The management of Eris Lifesciences said the phased rollout of the semaglutide portfolio, including pen-based products and obesity-focused SKUs, is expected to support growth momentum going ahead.
The management of Eris Lifesciences said the phased rollout of the semaglutide portfolio, including pen-based products and obesity-focused SKUs, is expected to support growth momentum going ahead.